Picard Medical, Inc. and SynCardia Systems LLC CEO to Present at CSI Focus D-HF 2025 in Frankfurt, Germany

TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference, scheduled for December 5^th through 6^th, 2025 in Frankfurt, Germany.

Read more at globenewswire.com